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SYNOPSIS 
Mycobacteria are multifaceted pathogens capable of causing both acute disease as 
well as an asymptomatic latent infection. Protective immunity against pathogenic 
mycobacteria depends principally on cell-mediated immunity executed by efficient anti-
infectious functions of type 1 T helper (Th1) subset of CD4+ T cells. The polarization of Th1 
responses is orchestrated by IL-12 secreted by antigen presenting cells (APCs) such as 
macrophages and dendritic cells (DCs).  A hallmark of Th1 type CD4+ T cells is the 
production of IFN-γ that activates plethora of innate cell-mediated immunity. It is well 
known that cytokines such as IFN-γ, IL-12 and TNF-α are required for control of 
mycobacterial infection in humans as well as in mice. However, it remains unclear that why 
the immune response controls mycobacteria, but does not eradicate infection suggesting 
critical roles for series of survival strategies employed by pathogenic mycobacteria. In 
general, these evasion strategies include blockade of phagosome-lysosome fusion, secretion 
of ROI antagonistic proteins like superoxide dismutase & catalase, inhibition of processing 
of its antigens for presentation to T cells, induced secretion of immunosuppressive cytokines 
like IL-10 and TGF-β etc. that ultimately suppress the secretion of IL-12 and IFN-γ from 
APCs and T cells respectively, culminating in a skewed Th1/Th2 balance towards 
unprotective Th2 responses. Th2 cells secrete IL-4, IL-5, IL-9, IL-10 and IL-13 but are 
deficient in clearing intracellular infections including pathogenic mycobacteria. This 
eventually leads to inhibition of host’s immuno-protective responses with concomitant 
increase in the vulnerability to chronic mycobacterial infection. 
In this intricate process, modulation of cyclooxygenase-2 (COX-2) levels, a key 
enzyme catalyzing the rate-limiting step in the inducible production of prostaglandin E2 
(PGE2), by mycobacteria like Mycobacterium bovis BCG assumes critical importance in 
 
Synopsis 
 viii
influencing the overall host immune response. PGE2, an immunosuppressive member of 
prostaglandin family, is known to restrain production of IL-12, as well as reactive oxygen 
intermediates. PGE2-mediated inhibition of IL-12R, diminishes IL-12 responsiveness of 
macrophages and dendritic cells. PGE2 also inhibits the secretion of IFN-γ, which is 
important in activating T cells and macrophages. In contrast, PGE2 promotes IL-10 
production by macrophages, dendritic cells and Th1-to-Th2 shift of acquired immune 
responses by inhibiting IL-2 and enhancing IL-4 production. Albeit, mitogen-activated 
protein kinase (MAPK) and nuclear factor-kappa B (NF-κB) signaling pathways are 
generally believed to be involved, little is known about the signaling molecules playing 
significant roles upstream of MAPK and NF-κB pathways during mycobacteria triggered 
COX-2 expression. Further, information on early receptor proximal signaling mechanisms 
essential during mycobacteria mediated induction of COX-2 remains scanty. 
In this regard, signaling cascade triggered upon recognition of mycobacterial 
components by pattern recognition receptors (PRR) signify as critical event in overall 
regulation of cell fate decisions.  PRR like Toll like receptor (TLR2) and nucleotide-binding 
oligomerization domain 2 (NOD2) are two nonredundant recognition mechanisms of 
pathogenic mycobacteria. Several components of mycobacteria have been identified as being 
responsible for TLR2-dependent activation including 19-kDa lipoprotein, lipomannan etc.; 
while NOD2 recognizes mycobacterial peptidoglycans through its interaction with muramyl 
dipeptide (MDP). Interestingly, although mycobacteria reside within phagolysosomes of the 
infected macrophages, many cell wall antigens like lipoarabinomannan (LAM), 
phosphatidyl-myo-inositol mannosides (PIM), trehalose 6,6′-dimycolate (TDM; cord factor), 
PE/PPE family proteins etc., are released and traffic out of the mycobacterial phagosome 
platform into endocytic compartments. Importantly, these antigens could gain access to the 
extracellular environment in the form of exocytosed vesicles. In this perspective, PIM 
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represents a variety of phosphatidyl-myo-inositol mannosides (PIM) 1-6 containing 
molecules and are integral component of the mycobacterial envelope. Further, PIM2 is a 
known TLR2 agonist and reported to activate NF-κB, AP-1, and MAPK suggesting that 
mycobacterial envelope antigen PIM2 could modulate the inflammatory responses similar to 
mycobacteria bacilli. In this context, we explored the signaling events modulated by M. bovis 
BCG, and role for TLR2 and NOD2 in this intricate process, to trigger the expression of 
COX-2 in macrophages.  
Our studies demonstrated that M. bovis BCG triggered TLR2-dependent signaling 
leads to COX-2 expression and PGE2 secretion in vitro in macrophages and in vivo in mice. 
Further, the presence of PGE2 could be demonstrated in sera or CSF of tuberculosis patients. 
Similarly, mycobacterial TLR2 agonist PIM2 and NOD2 ligand MDP triggered COX-2 
expression in macrophages. The induced COX-2 expression in macrophages either by M. 
bovis BCG or PIM2 or MDP was dependent on NF-κB activation, which was in turn 
mediated by iNOS/NO and Wnt-β-Catenin dependent participation of the members of 
Notch1-PI3K signaling cascade. Importantly, loss of iNOS activity either in iNOS null 
macrophages or by pharmacological intervention in wild type macrophages severely 
abrogated M. bovis BCG ability to trigger the generation of Notch1 intracellular domain 
(NICD) as well as activation of PI3K signaling cascade. On contrary, treatment of 
macrophages with SIN-1, an NO donor, resulted in a rapid increase in generation of NICD, 
activation of PI3K pathway as well as the expression of COX-2. Interestingly, 
pharmacological inhibition as well as siRNA mediated knockdown of Wnt-β-Catenin 
signaling compromised ability of M. bovis BCG to induce activation of Notch1-PI3K 
signaling and drive COX-2 expression. Concomitantly, activation of Wnt-β-Catenin 
signaling by LiCl triggered activation of Notch1 and PI3K pathway as well as COX-2 
expression. Stable expression of NICD in RAW 264.7 macrophages resulted in augmented 
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expression of COX-2. Further, signaling perturbation experiments suggested involvement of 
the cross-talk of Notch1 with PI3K signaling cascade. In this perspective, we propose TLR2 
and NOD2 as two major receptors involved in mycobacteria mediated activation of Notch1-
PI3K signaling, and the activation of iNOS/NO and Wnt-β-Catenin signaling axis as 
obligatory early receptor proximal signaling events during mycobacteria induced COX-2 
expression in macrophages.  
Functional characterization of mycobacterial antigens that are potent modulators of 
host immune responses to pathogens by virtue of induced expression of COX-2 assumes 
critical importance for deciphering pathogenesis of mycobacterial diseases as well as to 
identify novel therapeutic targets to combat the disease. In this context, a group of novel 
antigens carried by M. tuberculosis that are expressed upon infection of macrophages belong 
to PE and PPE family of proteins. Ten percent of the coding capacity of M. tuberculosis 
genome is devoted to the PE and PPE gene family members, exemplified by the presence of 
Pro-Glu (PE) and Pro-Pro-Glu (PPE) motifs near the N-terminus of their gene products. 
Many members of the PE family exhibit multiple copies of polymorphic guanine-cytosine–
rich sequences (PGRS) at the C-terminal end, which are designated as the PE_PGRS family 
of proteins. A number of PE/PPE proteins associate with the cell wall and are known to 
induce strong T & B cell responses in humans. However information related to effects of 
PE/PPE antigens on the maturation and functions of human dendritic cells and eventual 
modulation of T cell responses as well as underlying signaling events remains obscure. 
Our results demonstrated that two cell wall associated/secretory PE_PGRS proteins 
PE_PGRS 17, PE_PGRS 11 and PPE family protein PPE 34 recognize TLR2, induce 
maturation and activation of human dendritic cells and enhance the ability of dendritic cells 
to stimulate CD4+ T cells. In addition, tuberculosis patients were found to have a high 
frequency of T cells specific to PE_PGRS and PPE antigens. We further found that PE/PPE 
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proteins-mediated activation of dendritic cells involves participation of ERK1/2, p38 MAPK 
and NF-κB signaling pathways. While, PE_PGRS antigens-matured dendritic cells secreted 
high amounts of inflammatory cytokine IL-12, PPE 34 triggered maturation of dendritic cells 
was associated with secretion of high amounts of anti-inflammatory cytokine IL-10 but not 
the Th1-polarizing cytokine IL-12. Consistent with these results, PPE 34-matured dendritic 
cells favored secretion of IL-4, IL-5 and IL-10 from CD4+ T cells and contributed to Th2 
skewed cytokine balance ex vivo in healthy individuals and in patients with pulmonary 
tuberculosis. Interestingly, PPE 34-skewed Th2 immune response involved induced 
expression of COX-2 in dendritic cells. Our results suggest that by inducing differential 
maturation and activation of human dendritic cells, PE/PPE proteins could potentially 
modulate the initiation of host immune responses against mycobacteria. 
Taken together, our observations clearly signify the potential role for TLR2 and 
NOD2 triggering by M. bovis BCG in activating receptor proximal Notch1-PI3K signaling 
during induced COX-2/PGE2 expression which represents a crucial immune subversion 
mechanism employed by mycobacteria in order to suppress or attenuate host immune 
responses. Further, differential maturation of human dendritic cells by PE_PGRS and PPE 
antigens as well as their ability to stimulate CD4+ T cells towards Th1 and Th2 phenotype 
respectively, improves our understanding about host-mycobacteria interactions and clearly 
paves a way towards the development of novel combinatorial therapeutics.  
 
 
 
